Dr. Roy S. Herbst is widely recognized for his leadership and expertise in lung cancer treatment and research, particularly for the successful development of novel (immuno)therapies, including gefitinib, cetuximab, bevacizumab and axitinib. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. He currently holds the positions of Ensign Professor of Medicine (Medical Oncology), Chief of Medical Oncology, Deputy Director, and Associate Director of Translational Research at the Yale Cancer Center. He previously served on the boards of the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC), and has been involved with the National Cancer Institute’s Thoracic Malignancy Steering Committee since 2012. Before joining Yale, he was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology at The University of Texas MD Anderson Cancer Center (UT-MDACC). Dr. Herbst holds a PhD from The Rockefeller University and a MS from Harvard University. He completed his fellowships at Brigham and Women’s Hospital and the Dana Farber Cancer Institute, and a residency at Brigham and Women’s Hospital. Dr. Herbst received his MD from Cornell University Medical College and earned a MS and BS degree from Yale University

WordPress Cookie Notice by Real Cookie Banner